Integrated BioPharma Reports Results for its Quarter Ended March 31, 2026
Rhea-AI Summary
Integrated BioPharma (OTCQX: INBP) reported results for the quarter ended March 31, 2026. Quarterly revenue was $10.1M (down 27.3% vs. Q1 2025) and nine-month revenue was $34.1M (down 15.2% vs. prior year). The company recorded a quarterly operating loss of $1.1M and net loss of $0.8M. Gross profit for the quarter was negative $0.3M. Revenue from two largest contract-manufacturing customers represented approximately 90% of nine-month revenue in 2026.
AI-generated analysis. Not financial advice.
Positive
- Revenue visibility from two large customers representing ~90% of nine-month 2026 revenue
- Nine-month revenue remained $34.1M, indicating ongoing contract manufacturing activity
Negative
- Quarterly revenue declined 27.3% year-over-year to $10.1M
- Nine-month revenue declined 15.2% year-over-year to $34.1M
- Operating loss of $1.1M in Q1 2026 versus operating income of $0.7M in Q1 2025
- Net loss of $0.8M for Q1 2026 versus net income of $0.6M in Q1 2025
News Market Reaction – INBP
On the day this news was published, INBP declined 0.60%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
HILLSIDE, NJ / ACCESS Newswire / May 8, 2026 / Integrated BioPharma, Inc. ((OTCQX:INBP)) (the "Company" or "INBP") reports its financial results for the quarter ended March 31, 2026.
Revenue for the quarter ended March 31, 2026 was
Revenue for the nine-month period ended March 31, 2026 was
For the quarters ended March 31, 2026 and 2025, the Company had a net loss of
For the nine-month periods ended March 31, 2026 and 2025, the Company had a net loss of
"Our revenue decreased by approximately
A summary of our financial results for the three months and nine months ended March 31, 2026 and 2025 follows:
INTEGRATED BIOPHARMA, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except share and per share amounts)
(Unaudited)
Three Months Ended | Nine Months Ended | |||||||||||||||
March 31, | March 31, | |||||||||||||||
2026 | 2025 | 2026 | 2025 | |||||||||||||
Total revenue | $ | 10,107 | $ | 13,947 | $ | 34,076 | $ | 40,178 | ||||||||
Cost of sales | 10,383 | 12,396 | 33,304 | 36,085 | ||||||||||||
Gross profit | (276 | ) | 1,551 | 772 | 4,093 | |||||||||||
Selling and administrative expenses | 809 | 812 | 2,608 | 2,662 | ||||||||||||
Operating (loss) income | (1,085 | ) | 739 | (1,836 | ) | 1,431 | ||||||||||
Other income, net | 50 | 39 | 123 | 36 | ||||||||||||
(Loss) income before income taxes | (1,035 | ) | 778 | (1,713 | ) | 1,467 | ||||||||||
Income tax (benefit) expense, net | (198 | ) | 167 | (237 | ) | 481 | ||||||||||
Net (loss) income | $ | (837 | ) | $ | 611 | $ | (1,476 | ) | $ | 986 | ||||||
Net (loss) income per share: | ||||||||||||||||
Basic | $ | (0.03 | ) | $ | 0.02 | $ | (0.05 | ) | $ | 0.03 | ||||||
Diluted | $ | (0.03 | ) | $ | 0.02 | $ | (0.05 | ) | $ | 0.03 | ||||||
Weighted average common shares outstanding: | ||||||||||||||||
Basic | 31,059,610 | 30,300,720 | 31,059,610 | 30,190,869 | ||||||||||||
Diluted | 31,059,610 | 31,514,591 | 31,059,610 | 30,960,916 | ||||||||||||
About Integrated BioPharma Inc. (INBP)
Integrated BioPharma, Inc. ("INBP") is engaged primarily in the business of manufacturing, distributing, marketing and sales of vitamins, nutritional supplements and herbal products. Further information is available at ir.ibiopharma.com.
This document contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties, as well as assumptions, that, if they never materialize or prove incorrect, could cause the results of INBP to differ materially from those expressed or implied by such forward-looking statements. Forward-looking statements generally are identified by the words "expects," "anticipates," believes," intends," "estimates," "should," "would," "strategy," "plan" and similar expressions. All statements other than statements of historical fact are statements that could be deemed forward-looking statements and are not guarantees of future performance. Such statements speak only as of the date hereof, are subject to change and should not be relied upon for investment purposes. INBP undertakes no obligation to revise or update any statements for any reasons. The risks, uncertainties and assumptions include, among others, changes in general economic and business conditions; loss of market share through competition; introduction of competing products by other companies; the timing of regulatory approval and the introduction of new products by INBP; changes in industry capacity; pressure on prices from competition or from purchasers of INBP's products; regulatory changes in the pharmaceutical manufacturing industry and nutraceutical industry; regulatory obstacles to the introduction of new technologies or products that are important to INBP; availability of qualified personnel; the loss of any significant customers or suppliers; inflation, including inflationary pressures from any tariffs, and tightened labor markets; our ability to expand our customer base and other risks and uncertainties described in the section entitled "Risk Factors" in INBP's most recent Annual Report on Form 10-K and its subsequent Quarterly Reports on Form 10-Q. Accordingly, INBP cannot give assurance that any of the events anticipated by the forward-looking statements will transpire or occur, or if any of them do so, what impact they will have on the results of operations or financial condition of INBP.
Contact: Dina Masi, CFO
Integrated BioPharma, Inc.
investors@ibiopharma.com
888.319.6962
SOURCE: Integrated BioPharma, Inc.
View the original press release on ACCESS Newswire